Posted in

New CT Predictor for Sarcoma Lung Mets Survival

•Posted inRadiology

Soft tissue and bone sarcomas frequently metastasize to the lungs. Consequently, early and accurate prognostic assessment is critical. A new study investigated baseline CT imaging parameters to predict survival in patients with Sarcoma Lung Metastases. Researchers found a clear and independent link between the number of pulmonary lesions and Overall Survival (OS). Therefore, a simple imaging assessment holds significant clinical relevance for treatment planning.

Core Findings on Sarcoma Lung Metastases

This study included 100 consecutive sarcoma patients treated between 2016 and 2021. Patients without baseline CT, prior lung surgery, or systemic therapy were excluded. The median Overall Survival was 22.1 months. Furthermore, the median Progression-Free Survival (PFS) was 5.8 months. Parameters related to tumor burden, such as long-axis measurement or total volume, were not found to be prognostic for OS or PFS. The Hazard Ratios (HR) for these tumor burden measurements ranged from 0.724 to 1.354 (p-values 0.265–0.975). Therefore, measuring tumor size alone does not provide the necessary prognostic data.

However, the number of pulmonary lesions proved to be a significant predictor. Specifically, patients with five or more lesions showed a shorter OS. In the multivariate analysis, having ≥5 lesions had a strong Hazard Ratio of 3.478 (95% CI: 1.509–8.302, p = 0.004). This finding establishes the lesion count as an independent prognostic factor for OS. Similarly, other research consistently shows that fewer lung nodules—often three or less—correlate with a more favorable prognosis for sarcoma patients.

Prognostic Value of CT Nodule Count in Sarcoma Lung Metastases

The study clearly demonstrated that the pulmonary lesion count independently predicted Overall Survival. Conversely, the number of lesions was significant for PFS only in the univariate analysis (HR 1.741, p=0.011). It did not maintain significance in the multivariate model for PFS (HR 1.530, p=0.555). Consequently, no imaging parameter independently predicted PFS in this cohort. The number of lung nodules is generally considered an important prognostic factor in the context of pulmonary metastasectomy for sarcomas.

Other clinical factors also influence post-metastasis survival. For instance, the ability to completely resect all metastatic disease is a major prognostic factor. Patients who receive complete surgical resection often have a much better median survival than those treated non-operatively. Furthermore, a disease-free interval of more than 12 months is often a favorable prognostic factor. Conversely, certain histologic subtypes, like liposarcoma and malignant peripheral nerve tumors, are associated with a worse prognosis.

Clinical Implications and Treatment Decisions

The key takeaway is the direct clinical relevance of this finding. Baseline CT imaging assessment of the number of pulmonary lesions provides valuable prognostic information. This information should inform treatment decisions for patients with soft tissue and bone sarcoma. Specifically, a high lesion count (≥5) suggests a need for more intensive management strategies or clinical trial enrollment. Chest CT is a recommended initial evaluation and surveillance tool due to the high risk of lung metastasis. Knowing the lesion count helps stratify patients for aggressive treatments like metastasectomy.

Frequently Asked Questions

Q1: Which baseline CT imaging parameter best predicted Overall Survival?

The number of pulmonary lesions independently predicted Overall Survival (OS) in patients with soft tissue and bone sarcoma. Having five or more lesions was strongly associated with shorter OS.

Q2: Did pulmonary tumor burden (volume or long axis) predict survival?

No. Tumor burden parameters, such as the total volume or long axis of the lesions, showed no independent prognostic value for either Overall Survival or Progression-Free Survival.

Q3: What other factors influence survival in patients with sarcoma lung metastases?

Factors like the ability to completely resect the metastatic disease, a longer disease-free interval before metastasis, and the specific sarcoma histologic subtype are also known to significantly influence survival outcomes.

References

  1. Klambauer K et al. Baseline CT imaging parameters predicting overall and progression-free survival for patients with pulmonary metastases from soft tissue and bone sarcoma. Eur Radiol. 2026 Jan 03. doi: 10.1007/s00330-025-12289-3. PMID: 41483204.
  2. Billingsley KG et al. Pulmonary Metastases From Soft Tissue Sarcoma: Analysis of Patterns of Disease and Postmetastasis Survival. Ann Surg. 1999 May;229(5):602-12.
  3. Rizk J et al. Lung metastasis in soft tissue sarcomas: survival and risk factors using the SEER database. J Cancer Metastasis Treat 2024;10:11.
  4. Park BJ et al. Long-term results after resection for soft tissue sarcoma pulmonary metastases. Interact Cardiovasc Thorac Surg. 2011 Nov;13(5):509-13.
  5. Ghadimi M et al. Survival and prognostic factors following pulmonary metastasectomy for sarcoma. World J Surg Oncol. 2012;10:144.
  6. Lin YC et al. CT features of osteosarcoma lung metastasis: a retrospective study of 127 patients. Br J Radiol. 2019 Jul;92(1099):20180975.
  7. Wade A et al. The diagnosis of pulmonary metastases on chest computed tomography in primary bone sarcoma and musculoskeletal soft tissue sarcoma. J Bone Oncol. 2016 Jun 1;5(2):98-106.
  8. American College of Radiology. Imaging of Pulmonary Metastases. Medscape Reference.
  9. Nijland M et al. Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy. Acta Oncol. 2014 Dec;53(12):1618-24.